指南与共识浆细胞疾病

国际骨髓瘤学会/国际骨髓瘤工作组关于高危多发性骨髓瘤定义的共识推荐

International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.
指南 / 共识 · J Clin Oncol · 2025-06-09

国际骨髓瘤学会与国际骨髓瘤工作组召集专家小组,基于分子/基因组检测新证据、更新临床数据与当代风险分层概念,重新审视高危多发性骨髓瘤(HRMM)定义,提出共识基因组分期(CGS),依据至少一项特定异常判定HRMM。

要点

  • 传统预后因素在新型三药/四药治疗时代已不能准确判断预后,风险分层需细化。
  • 专家组提出HRMM共识基因组分期(CGS),依赖至少一项特定基因组/临床异常。
  • CGS标准包括del(17p)克隆分数>20%和/或TP53突变、特定IgH易位伴1q+和/或del(1p32)等。

核心结论

  • 专家组提出高危多发性骨髓瘤的共识基因组分期(CGS),依据至少一项特定异常判定HRMM。

研究设计与样本

  • 国际骨髓瘤学会与国际骨髓瘤工作组召集专家小组,基于分子/基因组检测新证据、更新临床数据与当代风险分层概念制定共识推荐。

主要发现

  • 传统基于旧疗法的预后因素在新型三药或四药治疗时代已不能准确捕捉预后。
  • 当前常规实践中的HRMM识别基于修订版国际分期系统(R-ISS),联合广泛可及的血清生物标志物与荧光原位杂交检测的染色体异常。

关键数值与推荐

  • CGS标准1:del(17p)克隆分数>20%和/或TP53突变。
  • CGS标准2:IgH易位包括t(4;14)、t(14;16)或t(14;20)伴1q+和/或del(1p32)。
  • CGS标准3:单等位del(1p32)伴1q+或双等位del(1p32)。
  • CGS标准4:β2微球蛋白≥5.5 mg/L伴肌酐正常(<1.2 mg/dL)。

临床怎么用

  • 常规实践中HRMM识别基于R-ISS,联合血清生物标志物与荧光原位杂交检测的染色体异常。
  • 专家组提出CGS用于定义HRMM,依据至少一项特定基因组或临床异常。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite significant improvements in survival of patients with multiple myeloma (MM), outcomes remain heterogeneous, and a significant proportion of patients experience suboptimal outcomes. Importantly, traditional prognostic factors based on data from patients treated with older therapies no longer capture prognosis accurately in the contemporary era of novel triplet or quadruplet therapies. Therefore, risk stratification requires refinement in the context of available and investigational treatment options in routine practice and clinical trials, respectively. The current identification of high-risk MM (HRMM) in routine practice is based on the Revised International Staging System, which stratifies patients using a combination of widely available serum biomarkers and chromosomal abnormalities assessed via fluorescence in situ hybridization. In recent years, a substantial body of evidence concerning additional clinical, biological, and molecular/genomic prognostic factors has accumulated, along with new MM risk stratification tools and consensus reports. The International Myeloma Society, along with the International Myeloma Working Group, convened an Expert Panel with the primary aim of revisiting the definition of HRMM and formulating a practical and data-driven consensus definition, based on new evidence from molecular/genomic assays, updated clinical data, and contemporary risk stratification concepts. The Panel proposes the following Consensus Genomic Staging (CGS) of HRMM which relies upon the presence of at least one of these abnormalities: (1) del(17p), with a cutoff of >20% clonal fraction, and/or TP53 mutation; (2) an IgH translocation including t(4;14), t(14;16), or t(14;20) along with 1q+ and/or del(1p32); (3) monoallelic del(1p32) along with 1q+ or biallelic del(1p32); or (4) β2 microglobulin ≥5.5 mg/L with normal creatinine (<1.2 mg/dL).

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Avet-Loiseau H, Davies FE, Samur MK, et al. International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma. J Clin Oncol. 2025. PMID: 40489728. doi:10.1200/JCO-24-01893

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。